Sumitomo Pharma Co., Ltd.
4506
Rang in Aktien
#3222
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Aktienkurs
$12.27
Marktkapitalisierung
$5.51B
Veränderung (1 Tag)
2.20%
Veränderung (1 Jahr)
6.72%
Land
JP
Handel Sumitomo Pharma Co., Ltd. (4506)
Kategorie
Healthcare
Operative Marge für Sumitomo Pharma Co., Ltd. (4506)
Operative Marge zum October 2026 TTM: 10.05%
Laut den neuesten Finanzberichten und dem Aktienkurs von Sumitomo Pharma Co., Ltd. beträgt die aktuelle operative Marge (TTM) 10.05%. Am Ende des Jahres 2024 lag die operative Marge bei -112.60%.
Historie der operativen Marge von Sumitomo Pharma Co., Ltd. von 2005 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 10.05% | 39.20% |
| 2025 | 7.22% | -106.41% |
| 2024 | -112.60% | 712.41% |
| 2023 | -13.86% | -228.81% |
| 2022 | 10.76% | -22.03% |
| 2021 | 13.80% | -19.95% |
| 2020 | 17.24% | 36.83% |
| 2019 | 12.60% | -33.30% |
| 2018 | 18.89% | 47.35% |
| 2017 | 12.82% | 39.96% |
| 2016 | 9.16% | 46.09% |
| 2015 | 6.27% | -42.32% |
| 2014 | 10.87% | 50.97% |
| 2013 | 7.20% | 23.71% |
| 2012 | 5.82% | -28.68% |
| 2011 | 8.16% | -32.11% |
| 2010 | 12.02% | 1.86% |
| 2009 | 11.80% | -21.75% |
| 2008 | 15.08% | -13.53% |
| 2007 | 17.44% | 48.43% |
| 2006 | 11.75% | 77.49% |
| 2005 | 6.62% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.72% |
IN
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.